| Systematic (IUPAC) name | |
|---|---|
| 2-[2,6-difluoro-4-({2-[(phenylsulfonyl)amino]ethyl}thio)phenoxy]acetamide | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Investigational New Medicine |
| Identifiers | |
| CAS number | 141286-78-4 |
| ATC code | ? |
| PubChem | CID 6603828 |
| Synonyms | PEPA |
| Chemical data | |
| Formula | C16H16F2N2O4S2 |
| Mol. mass | 402.436 g/mol |
| SMILES | eMolecules & PubChem |
| |
|
PEPA is an ampakine drug which acts as an allosteric potentiator of AMPA receptor desensitisation,[1][2] which is up to 100x more potent than aniracetam in vitro.[3] It produces memory-enhancing effects in rats when administered intravenously.[4]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)